

ATX-Gx™ for your Next Antibody Discovery Campaign at MImAbs



Join the fastest growing in vivo human antibody discovery platform

- ATX-Gx™ is currently used by a rapidly growing community of discovery groups across Fortune 50 biopharma, small and medium biotech companies, and academic research labs
- MImAbs is an Alloy Certified Service Provider who can support licensees of the ATX-Gx™ platform on their discovery projects



Best-in-class immunocompetence across a suite of transgenic mice

- ATX-Gx™ platform is a suite of transgenic mice collectively engineered to drive the greatest potential diversity and broadest epitopic coverage of unique human antibodies binding to your target of interest
- The core transgenic platform was developed over the last 12 years—first inside a Fortune 10 biopharma and later at Alloy—with rigorous attention to animal health, immunocompetence, and freedom to operate



Groundbreaking business terms with access in as little as two weeks

- World's first royalty-free humanized mouse discovery platform
- Simple licensing process, ability to start working with ATX-Gx™ mice in as little as two weeks
- Permitted to design your own KO and bespoke genetic modifications for ATX-Gx™

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy's lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA with European labs in Cambridge, UK. As a reflection of Alloy's relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Schedule a 15-minute call to learn more: www.alloytx.com/bd

ATX-Gx™ Platform

A portfolio of highly immunocompetent strains that together offer (i) full human heavy chain repertoire, (ii) human kappa and human lambda chain repertoire, (iii) haplotype diversity, and (iv) limited immunodominance.

ATX-GK BL/6	Complete functional human Gamma heavy chain and Kappa light chain on a BL/6 background (MHC Haplotype H-2b); available today for custom KO strains
ATX-GK BALB/c	Complete functional human Gamma heavy chain and Kappa light chain on a BALB/c background (MHC Haplotype H-2d)
ATX-GK Mix	Complete functional human Gamma heavy chain and Kappa light chain on a mix BL/6 & BALB/c background (MHC Haplotypes H-2b & H-2d).
ATX-pGK	First half of human Gamma heavy with full human Kappa light chains on a BL/6 background (MHC Haplotype H-2b) to limit immunodominance
ATK-dGK	Q4-21 Second half of human Gamma heavy chains with full Kappa light chains on a BL/6 background (MHC Haplotype H-2b) to limit immunodominance
ATX-GL	Second half of human Gamma heavy chains with full Kappa light chains on a BL/6 background (MHC Haplotype H-2b) to limit immunodominance
ATX-HyperImmune	2022 Multiple ATX-Gx humanized transgenic lines engineered to generate human antibodies against high-homology targets

ATX-GK Case Study

Recent example of ATX-GK producing wild-type seroconversion levels and a highly diverse antibody output with single-digit nanomolar and sub-nanomolar lead human antibody binders.

